Table Graph
      published meta-analysis   sensitivity analysis   studies

lopinavir/ritonavir in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsNojomi, 2020 (REV) 2.04 [0.18; 23.27] Nojomi, 2020 2.04 [0.18; 23.27] 2.04[0.37; 11.41]Nojomi, 2020 (REV), Nojomi, 202020%200moderatenot evaluable viral clearance by day 14detailed resultsELACOI (Lopinavir/ritonavir), 2020 (REV) 0.54 [0.12; 2.48] 0.54[0.12; 2.48]ELACOI (Lopinavir/ritonavir), 2020 (REV)10%69NAnot evaluable viral clearance by day 7detailed resultsELACOI (Lopinavir/ritonavir), 2020 (REV) 0.92 [0.35; 2.47] 0.92[0.35; 2.47]ELACOI (Lopinavir/ritonavir), 2020 (REV)10%69NAnot evaluable severe COVID-19 occurrencedetailed resultsELACOI (Lopinavir/ritonavir), 2020 (REV) 3.28 [0.79; 13.64] 3.28[0.79; 13.64]ELACOI (Lopinavir/ritonavir), 2020 (REV)10%69NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-04-25 16:54 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 509 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons